Multidisciplinary Association for Psychedelic Studies (MAPS)

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

MAPS is currently sponsoring large-scale, FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which was designated a Breakthrough Therapy by the FDA in 2017. These studies are the final stage of research required before MAPS can submit a New Drug Application to the FDA for approval, anticipated in 2021.